1. Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis
- Author
-
Christian Trautwein, Philipp A. Reuken, Theresa H. Wirtz, Christoph Emontzpohl, EF Brandt, Marie-Luise Berres, Nilay Köse-Vogel, Christina Backhaus, Maximilian J. Brol, Michael Praktiknjo, Richard Bucala, Irina Bergmann, P Fischer, J Reißing, Johannes Chang, Henning W. Zimmermann, Christian Jansen, Jonel Trebicka, Robert Schierwagen, M. Teresa Koenen, Christian Stoppe, Ingo Kurth, Andreas Stallmach, Jürgen Bernhagen, Tony Bruns, Thomas Eggermann, and Kai Markus Schneider
- Subjects
medicine.medical_specialty ,Cirrhosis ,Survival ,AST, aspartate aminotransferase ,sCD74, soluble receptor CD74 ,Gastroenterology ,MELD, model for end-stage liver disease ,MIF, macrophage migration inhibitory factor ,CXCL10, C-X-C motif chemokine ,Model for End-Stage Liver Disease ,Spontaneous bacterial peritonitis ,WBC, white blood cell count ,ALT, alanine aminotransferase ,TIPS, transjugular intrahepatic portosystemic shunt ,Internal medicine ,Ascites ,Internal Medicine ,medicine ,Immunology and Allergy ,Decompensation ,ddc:610 ,lcsh:RC799-869 ,Inflammation ,Hepatology ,biology ,business.industry ,C-reactive protein ,SBP, spontaneous bacterial peritonitis ,Biomarker ,SNP, single nucleotide polymorphism ,medicine.disease ,Acute-on-chronic liver failure ,SDC, stable decompensated cirrhosis ,ACLF, acute-on-chronic liver failure ,SHR, subdistribution hazard ratio ,Liver cirrhosis ,CRP, C-reactive protein ,biology.protein ,Macrophage migration inhibitory factor ,lcsh:Diseases of the digestive system. Gastroenterology ,Liver function ,medicine.symptom ,HCC, hepatocellular carcinoma ,business ,Research Article ,UDC, unstable decompensated cirrhosis - Abstract
Background & Aims Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine and an important regulator of innate immune responses. We hypothesised that serum concentrations of MIF are associated with disease severity and outcome in patients with decompensated cirrhosis and acute-on-chronic liver failure (ACLF). Methods Circulating concentrations of MIF and its soluble receptor CD74 (sCD74) were determined in sera from 292 patients with acute decompensation of cirrhosis defined as new onset or worsening of ascites requiring hospitalisation. Of those, 78 (27%) had ACLF. Short-term mortality was assessed 90 days after inclusion. Results Although serum concentrations of MIF and sCD74 did not correlate with liver function parameters or ACLF, higher MIF (optimum cut-off >2.3 ng/ml) and lower concentrations of sCD74 (optimum cut-off, Graphical abstract, Highlights • MIF serum concentrations do not correlate with hepatic function but with systemic inflammation in decompensated cirrhosis patients. • MIF serum concentrations are independent of genetic MIF promoter polymorphisms in patients with decompensated cirrhosis. • MIF and sCD74 serum concentrations predict transplant-free 90-day survival in patients with decompensated cirrhosis. • Patients with decompensated cirrhosis and both high MIF and low sCD74 serum concentrations have impaired survival. • Patients with decompensated cirrhosis show a transhepatic gradient with higher MIF concentrations in right atrial blood.
- Published
- 2020
- Full Text
- View/download PDF